Introduction

During this season of gratitude, I want to take this opportunity to personally reflect on the past year. Eclipsebio continues to be at the forefront of RNA success, and I am deeply grateful to everyone who has made this possible. To begin, I want to thank our dedicated team of RNA experts for your unwavering commitment and dedication to our mission. Next, I'd like to thank our new and longstanding partners for trusting us to support your groundbreaking research and drug development programs.  

Thankful to our team

Every year, the Eclipsebio team amazes me with their ingenuity and passion for supporting our partners. This year has been no exception: 

• Our R&D and Bioinformatics teams have solved one of the biggest challenges for effective quality control of RNA-based medicines through the development of eSENSE dsRNA. eSENSE dsRNA is the only sequencing-based solution that provides quantification and actionable insights into dsRNA generation. 
• Our Services team has continued to go above and beyond to ensure that each partner gets the support they need to make their research or drug development a success. It has been humbling to travel to conferences around the world and be able to find partners who are grateful for our support, making the difference for their publication or preclinical checkpoints. 
• Our Commercial team has continued with their strong partner-first approach, dedicating themselves to addressing the core challenges our partners face. Through in-depth consultations, insightful partner interviews, and close collaboration with our R&D team, they have continued to help develop tailored solutions that truly meet our partners’ unique needs. 

This year we launched our eMERGE partnership platform, designed to support the successful development of RNA-based vaccines and therapies. The launch of eMERGE was a company-wide effort that required the dedication and perseverance of every single member of our team to make it a reality. eMERGE fills a major gap in current quality control and optimization approaches by using next-generation sequencing to fully characterize therapies and provide actionable insights for their improvement. As a result, the rapid adoption of eMERGE by biotechs working on the next life-saving vaccines to major biopharma developing cutting-edge therapies has been exciting to witness. 

Thankful to our partners

Eclipsebio would not be where it is today without the success of our partners. From our biopharma and biotech partners that are developing novel approaches to preventing and treating disease, to our academic partners making groundbreaking discoveries into the intricacies of RNA biology. This year has been full of achievements, some of the public successes of this year include: 

• Genentech used m6A-eCLIP to examine the role of m6A methylation in innate immunity. 
• The Slack Lab used miR-eCLIP to discover the role of miR-21 in liver disease. 
• The Rush Alzheimer’s Disease Center used RBP-eCLIP and m6A-eCLIP to profile the role of the protein YTHDF in Alzheimer’s Disease. 
• The Vella Lab used RBP-eCLIP to reveal the role of the protein TRA2β in regulating T cell biology. 

Conclusion

This Thanksgiving, I invite the Eclipsebio community to join me in celebrating these successes. Looking forward, I am excited for the milestones we’ll reach together in the coming year as we continue to propel advancements in RNA research and therapeutics. Here’s to each member of our team and our valued partners—thank you for your trust, collaboration, and inspiration.